PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). Read more about PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Read more about Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer. Read more about Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer.
Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. Read more about Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer. Read more about Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer.
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Read more about Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
Innovating Simpler and Less Toxic Frontline Management for Adults With ALL. Read more about Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer. Read more about Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Read more about Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. Read more about RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
